Clinical Trial Update: Study to Investigate the Safety/Tolerability and Pharmacokinetics/Pharmacodynamics of CKD-519 [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating the safety, tolerability, and pharmacokinetics/pharmacodynamics of CKD-519 in dyslipidemia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dyslipidemia

Drugs mentioned

• CKD-519

Snippet

Sponsor: Chong Kun Dang Pharmaceutical | Conditions: Dyslipidemia | Phase 1 | Status: COMPLETED